Literature DB >> 8462588

Cell adhesion to streptavidin via RGD-dependent integrins.

R Alon1, E A Bayer, M Wilchek.   

Abstract

Biotin-blocked streptavidin binds specifically (Kd approximately 3 x 10(-8) M) to cell surfaces, presumably via an RYD-containing sequence. This site is distinct from the biotin-binding cleft of the protein and bears high homology to the RGD-containing cell-binding domain of fibronectin. We show here that various cell types adhere to immobilized streptavidin and that the soluble protein interferes specifically with cell adhesion to fibronectin substrata (with an IC50 of about 1 x 10(-7) M) but less so to other adhesive glycoproteins (e.g., collagen type I, vitronectin). Immunochemical evidence combined with peptide competition studies demonstrated that cells bind to streptavidin primarily via the major fibronectin receptor (the alpha 5 beta 1 integrin). The results suggest that streptavidin acts as a relatively strict fibronectin mimetic, thus reflecting the great similarity in their respective RYD/RGD sequence and the immediate flanking regions. The bacterial protein emulates and competes with fibronectin and other extracellular matrix adhesive proteins in the initial recognition and binding to cell surfaces, but appears not to induce subsequent processes (e.g., anchorage and spreading). Streptavidin may thus represent a novel example of bacterial protein mimicry of a key adhesion motif.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8462588

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  7 in total

1.  A gel-based dual antibody capture and detection method for assaying of extracellular cytokine secretion: EliCell.

Authors:  Lisa A Spencer; Rossana C N Melo; Sandra A C Perez; Peter F Weller
Journal:  Methods Mol Biol       Date:  2005

2.  Induction of vaginal-resident HIV-specific CD8 T cells with mucosal prime-boost immunization.

Authors:  H-X Tan; A K Wheatley; R Esterbauer; S Jegaskanda; J J Glass; D Masopust; R De Rose; S J Kent
Journal:  Mucosal Immunol       Date:  2017-10-25       Impact factor: 7.313

3.  Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Lisa Y Wu; Jeonghoon Lee; Peter T A Reilly; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

4.  Neural stem cells improve intracranial nanoparticle retention and tumor-selective distribution.

Authors:  Rachael Mooney; Yiming Weng; Revathiswari Tirughana-Sambandan; Valerie Valenzuela; Soraya Aramburo; Elizabeth Garcia; Zhongqi Li; Margarita Gutova; Alexander J Annala; Jacob M Berlin; Karen S Aboody
Journal:  Future Oncol       Date:  2014-02       Impact factor: 3.404

5.  Inhibition of human scleral fibroblast cell attachment to collagen type I by TGFBIp.

Authors:  Lilian Shelton; Jody A Summers Rada
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-22       Impact factor: 4.799

6.  Optimized immunohistochemical analysis of cerebellar purkinje cells using a specific biomarker, calbindin d28k.

Authors:  Byung Joo Kim; So Yeon Lee; Hyung Woo Kim; Eun-Jung Park; Jun Kim; Sang Jeong Kim; Insuk So; Ju-Hong Jeon
Journal:  Korean J Physiol Pharmacol       Date:  2009-10-31       Impact factor: 2.016

7.  Internalization of novel non-viral vector TAT-streptavidin into human cells.

Authors:  Johanna Rinne; Brian Albarran; Juulia Jylhävä; Teemu O Ihalainen; Pasi Kankaanpää; Vesa P Hytönen; Patrick S Stayton; Markku S Kulomaa; Maija Vihinen-Ranta
Journal:  BMC Biotechnol       Date:  2007-01-02       Impact factor: 2.563

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.